RayKnowChina Research Map
Shortlist0

Anyang

Anyang Tumor Hospital

安阳市肿瘤医院

Listed for 2 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Anyang Tumor Hospital

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Oesophageal squamous cell carcinoma食管鳞状细胞癌17 papers led
  2. Stomach cancer胃癌10 papers led

Not listed for: Nasopharyngeal carcinoma, Hepatocellular carcinoma, Hepatoblastoma, Retinoblastoma, Chordoma, Osteosarcoma, Gastrointestinal stromal tumour, Neuroblastoma, Ewing sarcoma, Multiple myeloma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Idiopathic pulmonary fibrosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Alport syndrome, IgA nephropathy, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 17 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.6%.

Papers led
17
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
5
led by another institution
Papers led per year
2021: 1120212022: 6620222023: 1120232024: 4420242025: 552025

1 hospital in Anyang for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma

Open trials with this hospital 5

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
    Phase
    Phase 3
    Started
    2025-03
    Registry
    NCT06644781

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesAnyang, Beijing, Changchun, Chengdu, Fuzhou, Hangzhou, Harbin, Hefei, Jinan, Jining, Linyi, Luoyang, Nanning, Shantou, Shenyang, Tianjin, Wuhan, Xiamen, Xinxiang, Yangzhou, Zhengzhou

  2. Recruiting
    Efficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2024-03
    Registry
    NCT06342167

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesAnyang, Fuzhou, Taizhou, Tianjin, Xinxiang, Yinchuan

  3. Recruiting
    Induction Chemoimmunotherapy Combined With Chemoradiotherapy in Esophageal Cancer
    Phase
    Phase 2
    Started
    2024-05
    Registry
    NCT06421376

    Age 18 years to 80 years (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMS; 2 listed hospitals as study sitesAnyang, Beijing, Xinxiang

  4. Recruiting
    Chemoradiotherapy in Unresectable Esophageal Cancer
    Phase
    Phase 1/Phase 2
    Started
    2019-10
    Registry
    NCT04278287

    Age 18 years to 75 years (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMS; 4 listed hospitals as study sitesAnyang, Beijing, Changsha, Nanjing

  5. Recruiting
    Chemoradiation Versus Esophagectomy for Locally Advanced Esophageal Cancer
    Phase
    N/A
    Started
    2016-11
    Registry
    NCT02972372

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Henan University of Science and Technology; 1 listed hospital as study siteAnyang, Luoyang

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesMolecular markers & genomicsNeoadjuvant & combined treatmentImaging & AI
Departments in papersRadiation oncologyMedical oncologyPathology / laboratory medicineGastroenterology / hepatology
Papers it led17
  1. CBX6 induces CD8+ T cell exhaustion and tumor development in esophageal squamous cell carcinoma through SMARCD1-mediated CCL8 secretion and lactate efflux.2025Cell biology and toxicologyFree full text
  2. EVA1A facilitates glycolysis in esophageal squamous cell carcinoma to boost PLAU histone lactylation and dampen CD8+ T cell activity.2025Expert review of clinical immunology
  3. Harnessing Calmodulin-Related Genes to Build a Prognostic Model in Esophageal Squamous Cell Carcinoma for a Comprehensive Analysis of Single-Cell Immune Characteristics and Drug Efficacy.2025Journal of immunotherapy (Hagerstown, Md. : 1997)
  4. Effects of FAP+ fibroblasts on cell proliferation migration and immunoregulation of esophageal squamous carcinoma cells through the CXCL12/CXCR4 axis.2025Molecular and cellular biochemistry
  5. Feasibility and tolerability of anlotinib plus PD-1 blockades as rechallenge immunotherapy in previously treated advanced ESCC: a retrospective study.2025The oncologistFree full text
  6. circRNA6448-14/miR-455-3p/OTUB2 axis stimulates glycolysis and stemness of esophageal squamous cell carcinoma.2024AgingFree full text
  7. Establishment and validation of the prognostic risk model based on the anoikis-related genes in esophageal squamous cell carcinoma.2024Annals of medicineFree full text
  8. Diagnosis of Esophageal Squamous Cell Carcinoma by High-Performance Serum Metabolic Fingerprints: A Retrospective Study.2024Small methods
  9. The significance of consolidation chemotherapy after concurrent chemoradiotherapy in esophageal squamous cell carcinoma: a randomized controlled phase III clinical trial.2024Thoracic cancerRCTFree full text
  10. A one-dimensional convolutional neural network based deep learning for high accuracy classification of transformation stages in esophageal squamous cell carcinoma tissue using micro-FTIR.2023Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy
  11. Clinical impact of Fn-induced high expression of KIR2DL1 in CD8 T lymphocytes in oesophageal squamous cell carcinoma.2022Annals of medicineFree full text
  12. A multi-center, single-arm, phase II study of anlotinib plus paclitaxel and cisplatin as the first-line therapy of recurrent/advanced esophageal squamous cell carcinoma.2022BMC medicineFree full text
  13. Efficacy and Safety of Apatinib plus Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cancer: A Phase II Trial.2022BioMed research internationalFree full text
  14. Development and Validation of a Nomogram for Predicting Overall Survival to Concurrent Chemoradiotherapy in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma.2022BioMed research internationalRCTFree full text
  15. A tumor immune microenvironment-related integrated signature can predict the pathological response and prognosis of esophageal squamous cell carcinoma following neoadjuvant chemoradiotherapy: A multicenter study in China.2022International journal of surgery (London, England)
  16. Rapid and sensitive detection of esophageal cancer by FTIR spectroscopy of serum and plasma.2022Photodiagnosis and photodynamic therapy
  17. Clinical Significance of Fusobacterium nucleatum Infection and Regulatory T Cell Enrichment in Esophageal Squamous Cell Carcinoma.2021Pathology oncology research : PORFree full text
Chinese-language papers (not in the count)1
  1. [Long-term efficacy and safety of simultaneous integrated boost radiotherapy in non-operative esophageal squamous cell carcinoma: a multicenter retrospective data analysis (3JECROG R-05)].2021Zhonghua zhong liu za zhi [Chinese journal of oncology]
All its trials on ClinicalTrials.gov, any status21
  1. A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)RecruitingNCT06644781Study sitePhase 3Start 2025-03
  2. Induction Chemoimmunotherapy Combined With Chemoradiotherapy in Esophageal CancerRecruitingNCT06421376Study sitePhase 2Start 2024-05
  3. Efficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell CarcinomaRecruitingNCT06342167Study sitePhase 2Start 2024-03
  4. Chemoradiotherapy in Unresectable Esophageal CancerRecruitingNCT04278287Study sitePhase 1/Phase 2Start 2019-10
  5. Chemoradiation Versus Esophagectomy for Locally Advanced Esophageal CancerRecruitingNCT02972372Study siteN/AStart 2016-11
  6. Candonilimab (AK104) Plus Preoperative Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC)Status unknownNCT05896787Study sitePhase 2Start 2023-08
  7. A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell CarcinomaCompletedNCT06010303Study sitePhase 2Start 2023-11
  8. Clinical Trial to Evaluate the Safety and Effectiveness of TQB2618 Injection Combined Therapy in Patients With Advanced Esophageal Squamous Cell CarcinomaTerminatedNCT05834543Study sitePhase 1/Phase 2Start 2023-05
  9. Anlotinib Combined With TQB2450 (PD-L1 Inhibitor) in the Treatment of Advanced Esophageal Squamous Cell Carcinoma(ESCC)Status unknownNCT05038813Study sitePhase 2Start 2022-03
  10. A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy or Monotherapy in Patients With Advanced ESCCStatus unknownNCT05221658Study sitePhase 2Start 2022-08
  11. Real-world Experience of ICIs Plus Chemotherapy for Advanced ESCC.CompletedNCT05142709Study siteStart 2021-10
  12. TQB2450 Solution for Injection (TQB2450)+Paclitaxel+Cisplatin ± Anlotinib in the Treatment of Esophageal Cancer.Status unknownNCT05013697Study sitePhase 2Start 2021-09
  13. Camrelizumab Plus Neoadjuvant Chemotherapy or Chemoradiotherapy Versus Chemoradiotherapy in Resectable ESCC.Active, not recruitingNCT05043688Study sitePhase 3Start 2021-09
  14. Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell CarcinomaActive, not recruitingNCT04848753Study sitePhase 3Start 2021-05
  15. Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).TerminatedNCT04949256Study sitePhase 3Start 2021-07
  16. SI-B001 Combined With Irinotecan in the Treatment of Recurrent Metastatic Esophageal Squamous Cell Carcinoma.Active, not recruitingNCT05022654Study sitePhase 2Start 2021-12
  17. Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal CancerCompletedNCT04821765Study sitePhase 2Start 2020-10
  18. Paclitaxel and DDP Combined With Anlotinib in the First-line Treatment for Patients With Advanced Esophageal Squamous Cell Carcinoma(ESCC).Status unknownNCT04063683Study sitePhase 2Start 2019-10
  19. Performance of White Light, NBI and Iodine Staining Endoscopy in the Diagnosis of Esophageal LesionsStatus unknownNCT04170257Study siteN/AStart 2019-10
  20. A Study of CS1001 in Subjects With Esophageal Squamous Cell CarcinomaCompletedNCT04187352Study sitePhase 3Start 2019-12
  21. Neoadjuvant Chemotherapy Versus Surgery Alone for Esophageal Squamous Cell CarcinomaCompletedNCT02395705Study sitePhase 3Start 2015-06
More papers found outside PubMed (not counted)53
  1. 2131P Adebrelimab plus apatinib in advanced esophageal squamous cell carcinoma following immune checkpoint inhibitors: Preliminary results from cohort 3 of CAP 02 study2025Annals of Oncologyarticle
  2. 305P Safety and efficacy of endoscopic resection followed by adjuvant chemoradiotherapy (ERACT) for organ preservation in early-stage oesophageal squamous cell carcinoma with high-risk features: A prospective, multicenter, phase II clinical2025Annals of Oncologyarticle
  3. Abstract 1945: High-sensitive gastrointestinal cancers early detection by cell-free DNA targeted methylation sequencing with an innovative modeling approach2025Cancer Researchconference-abstract
  4. Anlotinib plus benmelstobart as adjuvant therapy in patients with esophageal squamous cell carcinoma: A phase II clinical trial (ALTER-E005).2025Journal of Clinical Oncologyconference-abstract
  5. Camrelizumab plus with nimotuzumab in the second-line treatment of advanced esophageal squamous cell carcinoma: A single-arm, open-label phase II clinical trial.2025Journal of Clinical Oncologyarticle
  6. Efficacy and safety results of a multi-center phase II study of utidelone injection in combination with PD-1 inhibitor and chemotherapy for the first-line treatment of advanced gastric and esophagus cancers.2025Journal of Clinical Oncologyconference-abstract
  7. Prediction of Neoadjuvant Immunochemotherapy Response in Esophageal Squamous Cell Carcinoma Using Pd-L1 Expression Combined with Clinical Features: A Multicenter Study2025SSRN Electronic Journalpreprint
  8. Preliminary results of the ALTER-E009 study: Efficacy and safety of anlotinib combined with radiotherapy in patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC)—A multicenter, multi-cohort retrospective exp2025Journal of Clinical Oncologyconference-abstract
  9. The lost evidence: A phase III, multicenter randomized controlled trial of neoadjuvant chemotherapy paclitaxel plus cisplatin versus surgery alone for stage IIA–IIIB esophageal squamous cell carcinoma.2025Journal of Clinical Oncologyconference-abstract
  10. Updated results of the ALTER-E00 study: Efficacy and safety of anlotinib combined with radiotherapy in patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC): A multi-center, multi-cohort retrospective explor2025Journal of Clinical Oncologyarticle
  11. WITHDRAWN: 2143P Impact of first-line chemoimmunotherapy with or without radiotherapy on the prognosis of patients with locally advanced or metastatic esophageal squamous cell carcinoma: A multicenter, real-world, retrospective cohort study2025Annals of Oncologyretraction
  12. 187P Effectiveness, safety, and patterns of use of camrelizumab in advanced esophageal cancer: An individual patient data (IPD) pooled analysis of 987 patients from three prospective observational cohort studies2024Annals of Oncologyarticle
  13. A single-arm, open-label phase II clinical trial of SHR-1210 (camrelizumab) in combination with nimotuzumab in the second-line treatment of advanced esophageal squamous cell carcinoma.2024Journal of Clinical Oncologyconference-abstract
  14. Anlotinib plus TQB2450 as adjuvant therapy in patients with esophageal squamous cell carcinoma: A phase II study (ALTER-E005).2024Journal of Clinical Oncologyconference-abstract
  15. Anlotinib plus chemotherapy as first-line therapy for patients with gastrointestinal tumor with unresectable liver metastasis: Updated results from multi-cohort, multi-center phase II trial ALTER-G-001-cohort A.2024Journal of Clinical Oncologyconference-abstract
  16. Camrelizumab plus apatinib after progression on immune checkpoint inhibitors in patients with advanced esophageal squamous cell carcinoma (CAP 02 Re-challenge): A single-arm multicenter, phase II trial.2024Journal of Clinical Oncologyconference-abstract
  17. Chemotherapy plus camrelizumab versus chemotherapy alone as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (ESCORT-NEO): A multi-center, randomized phase III trial.2024Journal of Clinical Oncologyconference-abstract
  18. Dual-Omics Combined Hematological Parameters Model Predicts Pathological Complete Response in Esophageal Squamous Cell Carcinoma Patients after Neoadjuvant Chemoradiotherapy:A Multicenter Study2024SSRN Electronic Journalpreprint
  19. Efficacy and Safety of the Combination of Tislelizumab with Chemoradiotherapy in Oligorecurrence Esophageal Squamous Cell Carcinoma: A Prospective Phase II Study2024International Journal of Radiation Oncology*Biology*Physicsarticle
  20. Efficacy and safety of the combination of tisleizumab with chemoradiotherapy in oligorecurrence esophageal squamous cell carcinoma: A prospective phase II study.2024Journal of Clinical Oncologyconference-abstract
  21. First-line TQB2450 plus anlotinib combined with paclitaxel and cisplatin for advanced esophageal squamous cell carcinoma (ESCC): Update results of a multicenter phase II trial.2024Journal of Clinical Oncologyconference-abstract
  22. The feasibility and tolerability of anlotinib plus PD-1 blockades among patients with previously immunotherapy treated advanced esophageal squamous cell carcinoma (ESCC): Update results of a retrospective exploratory study.2024Journal of Clinical Oncologyconference-abstract
  23. Update results of anlotinib combined with TQB2450 (PD-L1 blockade) as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, multicenter, open-label phase II clinical trial.2024Journal of Clinical Oncologyconference-abstract
  24. “Pacific” Modality in Locally Advanced Esophageal Squamous Cell Carcinoma: A Propensity Score-Matched Analysis of a Real-World Multicenter Study2024International Journal of Radiation Oncology*Biology*Physicsarticle
  25. 1531P Update results of anlotinib combined with TQB2450 (PD-L1 blockade) as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, multicenter, open-label phase II clinical trial2023Annals of Oncologyarticle
  26. 1573P Involved field and elective nodal irradiation presented similar treatment efficiency in concurrent chemoradiation for locally advanced ESCC2023Annals of Oncologyarticle
  27. 482. SECOND-LINE OF CAMRELIZUMAB PLUS NIMOTUZUMAB IN ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC): A SINGLE-ARM, OPEN-LABEL, PHASE 2 TRIAL2023Diseases of the Esophagusarticle
  28. 95P A single-arm, multicenter phase II trial evaluating TQB2450 plus anlotinib combined with paclitaxel and cisplatin in first-line treatment of advanced esophageal squamous cell carcinoma (ESCC)2023Immuno-Oncology Technologyarticle
  29. A Comparison of Clinicopathologic Outcomes and Patterns of Lymphatic Spread across Neoadjuvant Chemotherapy, Neoadjuvant Chemoradiotherapy and Neoadjuvant Immunochemotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma2023International Journal of Radiation Oncology*Biology*Physicsarticle
  30. A phase 2 study of HLX07 as monotherapy or combination therapy in patients with locally advanced, unresectable, or metastatic esophageal squamous cell carcinoma.2023Journal of Clinical Oncologyconference-abstract
  31. Anlotinib combined with TQB2450 (PD-L1 blockade) as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, multicenter, open-label phase II clinical trial.2023Journal of Clinical Oncologyconference-abstract
  32. Anlotinib combined with nab-paclitaxel and cisplatin as neoadjuvant treatment (NAT) for esophageal squamous cell carcinoma (ESCC): Update results of a single-arm, phase II clinical trial.2023Journal of Clinical Oncologyconference-abstract
  33. Anlotinib plus PD-1 inhibitors as chemo-free therapy in advanced or metastatic esophageal cancer: Updated results from a retrospective real-world study.2023Journal of Clinical Oncologyconference-abstract
  34. Camrelizumab plus apatinib for immunochemotherapy-treated advanced esophageal squamous cell carcinoma: Preliminary results of cohort 2 in CAP 02 study.2023Journal of Clinical Oncologyconference-abstract
  35. Effectiveness and safety of camrelizumab in advanced esophageal cancer: A prospective multicenter observational cohort studies (ESCORT-RWS).2023Journal of Clinical Oncologyconference-abstract
  36. O-4 GEMSTONE-304: A phase 3 study of sugemalimab plus chemotherapy versus chemotherapy as first-line treatment of patients with unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC)2023Annals of Oncologyarticle
  37. P-162 Preliminary results of the feasibility and tolerability of anlotinib plus PD-1 blockades among patients with previously immunotherapy treated advanced esophageal squamous cell carcinoma (ESCC): A retrospective exploratory study2023Annals of Oncologyconference-abstract
  38. TQB2450 plus anlotinib combined with paclitaxel and cisplatin as first-line treatment of advanced esophageal squamous cell carcinoma (ESCC): Update results of a single-arm, multicenter phase Ⅱ trial.2023Journal of Clinical Oncologyconference-abstract
  39. Updated results of anlotinib combined with TQB2450 (PD-L1 blockade) as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, multicenter, open-label phase Ⅱ clinical trial.2023Journal of Clinical Oncologyconference-abstract
  40. 1252P Update results of anlotinib combined with nab-paclitaxel and cisplatin as neoadjuvant treatment for esophageal squamous cell carcinoma (ESCC): A single-arm, open-label phase Ⅱ clinical trial2022Annals of Oncologyarticle
  41. 164P TQB2450 plus anlotinib combined with paclitaxel and cisplatin as first-line treatment of advanced esophageal squamous cell carcinoma (ESCC): A single-arm, multicenter phase Ⅱ trial2022Immuno-Oncology Technologyarticle
  42. Anlotinib combined with nab-paclitaxel and cisplatin as neoadjuvant treatment for esophageal squamous cell carcinoma (ESCC): A single-arm, open-label phase II clinical trial.2022Journal of Clinical Oncologyconference-abstract
  43. Concurrent Chemoradiation of Different Doses (50.4 Gy vs. 59.4 Gy) and Different Target Field (ENI vs. IFI) for Locally Advanced Esophageal Squamous Cell Carcinoma: Results from a Randomized, Multicenter Phase Ⅲ Clinical Trial2022International Journal of Radiation Oncology*Biology*Physicsarticle
  44. Effectiveness of S-1–Based Chemoradiotherapy and S-1 Consolidation in Elderly Patients with Esophageal Squamous Cell Carcinoma: A Multicenter Randomized Phase III Clinical Trial2022International Journal of Radiation Oncology*Biology*Physicsarticle
  45. Effectiveness of S-1–Based Chemoradiotherapy and S-1 Consolidation in Elderly Patients with Esophageal Squamous Cell Carcinoma: A Multicenter, Open Label, Randomized Phase III Clinical Trial2022SSRN Electronic Journalpreprint
  46. Nimotuzumab plus concurrent chemo-radiotherapy versus chemo-radiotherapy in unresectable locally advanced esophageal squamous cell carcinoma (ESCC): Interim analysis from a prospective, randomized-controlled, double-blinded, multicenter, an2022Journal of Clinical Oncologyconference-abstract
  47. Real-world effectiveness of anlotinib in combination with PD-1 inhibitors as second-line or later therapy for advanced or metastatic esophageal squamous cell carcinoma.2022Journal of Clinical Oncologyconference-abstract
  48. Update results of paclitaxel and cisplatin in combination with anlotinib as first-line regimen for patients with advanced ESCC: A multicenter, single-arm, open-label phase Ⅱ clinical trial.2022Journal of Clinical Oncologyconference-abstract
  49. 659 AN SINGLE-ARM OPEN-LABEL PHASE II STUDY OF CAMRELIZUMAB PLUS APATINIB AS SECOND-LINE TREATMENT FOR ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA2021Diseases of the Esophagusarticle
  50. Camrelizumab in combination with apatinib as second-line treatment for advanced esophageal squamous cell carcinoma: A single-arm, open-label, phase II study.2021Journal of Clinical Oncologyconference-abstract
  51. Determining an Evidence-Based Surveillance Target and Respective Intervals for Esophageal Squamous Cell Carcinoma Following Screening: A Population-Based Cohort Study in China2021SSRN Electronic Journalpreprint
  52. Update results of paclitaxel and cisplatin in combination with anlotinib as first-line regimen for advanced esophageal squamous cell carcinoma (ESCC): A multicenter, single-arm, open-label phase Ⅱ clinical trial.2021Journal of Clinical Oncologyconference-abstract
  53. Update results of paclitaxel and cisplatin in combination with anlotinib as first-line regimen for patients with advanced ESCC: A multicenter, single-arm, open-label phase Ⅱ clinical trial.2021Journal of Clinical Oncologyconference-abstract

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 10 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.1%.

Papers led
10
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
3
led by another institution
Papers led per year
2021: 1120212022: 2220222023: 1120232024: 1120242025: 552025

1 hospital in Anyang for stomach cancer218 hospitals in China for stomach cancer

Open trials with this hospital 3

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
    Phase
    Phase 3
    Started
    2026-04
    Registry
    NCT07385703

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 62 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Changzhou, Chengde, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Nanchang, Nanchong, Nanjing, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xuzhou, Yangzhou, Zhengzhou

  2. Recruiting
    A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2022-01
    Registry
    NCT05150691

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 34 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chongqing, Guangzhou, Hangzhou, Hefei, Jinan, Nanning, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wenzhou, Wuhan, Wuxi, Xi'an, Xiamen, Xuzhou, Yantai, Zhengzhou

  3. Not yet recruiting
    AI-Assisted Novel rbcDNA Detection for Early Gastric Cancer Diagnosis
    Phase
    Not given
    Started
    2026-09
    Registry
    NCT07782294

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang University; 2 listed hospitals as study sitesAnyang, Hangzhou, Shanghai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesImaging & AIChemotherapy & combined treatmentPeritoneal spread & advanced disease
Departments in papersMedical oncologyPathology / laboratory medicineRadiation oncology
Papers it led10
  1. Involvement of long non-coding RNA NORAD in short-term poor prognosis of neoadjuvant chemotherapy in adenocarcinoma of esophagogastric junction.2025Annals of medicineFree full text
  2. NNMT suppresses H3K9me3 to facilitate malignant progression and drug resistance in gastric cancer.2025Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology
  3. Comprehensive analysis of risk factors and nomogram development for predicting hepatic metastasis following radical resection of adenocarcinoma of the esophagogastric junction.2025BMC gastroenterologyFree full text
  4. Case report: Patients with positive HER-2 amplification locally advanced gastroesophageal junction cancer achieved pathologic complete response with the addition of pembrolizumab to chemotherapy plus trastuzumab as neoadjuvant therapy.2025Frontiers in immunologyFree full text
  5. The Prognostic Significance of Vesicle-Mediated Transport-Related Genes as Risk Markers in Gastric Cancer.2025Journal of biochemical and molecular toxicology
  6. Clinicopathological characteristics of well-differentiated gastric cancer missed by endoscopy.2024Revista espanola de enfermedades digestivas
  7. A case report of SMARCA4-deficient undifferentiated tumor in the esophago-gastric junction.2023Asian journal of surgery
  8. Identification of a seven-cell cycle signature predicting overall survival for gastric cancer.2022AgingFree full text
  9. Effect of operation-introducing hyperthermic intraperitoneal chemotherapy on cellular immune function in patients with adenocarcinoma of the esophagogastric junction.2022Asian journal of surgery
  10. Effect of Radical Surgery for Advanced Adenocarcinoma of Esophagogastric Junction on Perioperative Cellular Cell Immunity.2021Journal of investigative surgery : the official journal of the Academy of Surgical Research
Chinese-language papers (not in the count)2
  1. [Long-term efficacy and safety of simultaneous integrated boost radiotherapy in non-operative esophageal squamous cell carcinoma: a multicenter retrospective data analysis (3JECROG R-05)].2021Zhonghua zhong liu za zhi [Chinese journal of oncology]
  2. [Increased expression of SEMA5B in gastric adenocarcinoma predicts poor prognosis: a study based on TCGA data].2021Zhonghua zhong liu za zhi [Chinese journal of oncology]
All its trials on ClinicalTrials.gov, any status6
  1. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingNCT07385703Study sitePhase 3Start 2026-04
  2. AI-Assisted Novel rbcDNA Detection for Early Gastric Cancer DiagnosisNot yet recruitingNCT07782294Study siteStart 2026-09
  3. A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid TumorsRecruitingNCT05150691Study sitePhase 1/Phase 2Start 2022-01
  4. Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) OverexpressionCompletedNCT05052801Study sitePhase 3Start 2022-03
  5. Clinical Study of SHR-1701 Plus Chemotherapy as Perioperative Treatment in Subjects With Gastric CancerTerminatedNCT05149807Study sitePhase 2/Phase 3Start 2022-01
  6. IN10018 Monotherapy or in Combination With Docetaxel in Gastric or GEJ AdenocarcinomaCompletedNCT05327231Study sitePhase 1Start 2020-07

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

安阳市肿瘤医院

Anyang Tumor Hospital

安阳

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
Anyang Tumor Hospital; Anyang Cancer Hospital; Anyang Tumour Hospital; Anyang Cancer Hospital of Henan Province; Anyang Tumor HospitalAnyang; Mianyang Cancer Hospital

Suggest a correctionDownload the data